Safety and Feasibility of a Novel Percutaneous Locoregional Injection Technique of Renal Cellular Therapy for Chronic Kidney Disease of Diabetes

Abstract

Early cell and gene therapies show promise to achieve positive treatment outcomes, primarily for cancer and hereditary conditions; however, there is a lack of therapeutic options for chronic organ failure, such as chronic kidney disease (CKD).1,2 CKD represents a growing global health crisis, predicted to affect more than 250 million people with type 2 diabetes as the leading cause in greater than 40% of selected populations and the dominant cause for end-stage kidney disease.3,4